High Efficacy Halts ViiV HIV Prevention Study Early
ViiV Hopes Faster Cabotegravir Approval Will Be The Result
Prospects have improved for ViiV’s long-acting, injectable cabotegravir to be approved early for HIV prevention after a Phase III trial was stopped early due to efficacy.
